The Joint Corp. (JYNT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite positive full-year financial performance and optimistic marketing initiatives, the decline in comp sales and lack of specific metrics on attrition and new patient adds raise concerns. The cautious approach to pricing increases and the shift from local to national marketing may not yield immediate results. The Q&A revealed some positive signs, but uncertainties remain. Overall, the market may react neutrally over the next two weeks.
Key Financial Performance
Revenue from continuing operations Increased 3.1% year-over-year. This improvement reflects the benefit of rightsizing costs.
Consolidated adjusted EBITDA Increased 7.8% year-over-year. This improvement reflects the benefit of rightsizing costs.
System-wide sales (Q4) Decreased 3.9% year-over-year to $140 million. This decline was largely due to lower new patient count.
Comp sales (Q4) Decreased 3.8% year-over-year. This decline was largely due to lower new patient count.
Adjusted EBITDA for consolidated operations (Q4) Grew 7.8% year-over-year to $3.6 million. This reflects improved operating leverage.
System-wide sales (Full Year) Flat year-over-year at $532 million.
Comp sales (Full Year) Declined 0.4% year-over-year.
Adjusted EBITDA for consolidated operations (Full Year) Increased 13.9% year-over-year to $13 million. This reflects improved operating leverage.
Revenue (Full Year) Increased to $54.9 million from $52.2 million in 2024. This was mainly due to additional marketing funding for national advertising.
Consolidated net income (Full Year) Increased $8.7 million year-over-year to $2.9 million, compared to a $5.8 million loss in 2024.
Net loss from continuing operations (Full Year) Improved to a loss of $268,000 compared to a loss of $1.6 million in 2024.
Adjusted EBITDA from continuing operations (Full Year) Improved to $3.1 million compared to $2.3 million in 2024.
Unrestricted cash and cash equivalents Remained strong at $23.6 million as of December 31, 2025, compared to $25.1 million in the prior year.
Clinic count Total clinic count was 960 at year-end, compared to 967 clinics in the prior year. This includes 29 new clinics opened, 41 refranchised, and 36 closed during 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Mobile App Enhancements: Introduced feature updates for the patient-facing mobile app, receiving an average rating of 4.91 out of 5 from over 23,000 patient surveys.
SEO and Digital Marketing: Improved search visibility and organic traffic through updates to digital marketing efforts, including a redesigned national blog and new microsites.
Refranchising Initiative: Signed agreements for the sale of 22 corporate-owned clinics for $1.5 million and entered a letter of intent for 5 more clinics, leaving 48 company-owned clinics.
Future Market Expansion: Plans to expand operations into new U.S. markets and international markets starting in 2027.
Cost Optimization: Achieved better-than-expected adjusted EBITDA performance by rightsizing costs and transitioning to a pure-play franchise model.
Marketing Strategy Shift: Shifted marketing focus to chiropractic care for pain relief, improving patient acquisition trends and retention.
Transformation Journey: On track to complete the first phase of the transformation journey, Joint 2.0, by the end of 2025, focusing on becoming a capital-light pure-play franchisor.
Long-term Strategic Goals: Planning for Joint 3.0 in 2027, which includes entering new channels, B2B opportunities, and integrating wearable technology data into treatment plans.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Refranchising Challenges: The company is in the process of refranchising its corporate-owned clinics, with 48 clinics remaining. There are risks associated with completing lease reassignments and finalizing sales agreements, which could delay the transition to a pure-play franchisor model.
Marketing Effectiveness: Despite efforts to improve marketing strategies, new patient acquisition trends remain lower than last year. This could impact revenue growth and system-wide sales.
Pricing Adjustments: The company is piloting price increases in select clinics, but there is uncertainty about how these changes will be received by customers and their impact on patient retention and sales.
Clinic Closures: The company closed 36 clinics in 2025 and expects a net decrease in clinic count in 2026. This could affect overall system-wide sales and brand presence.
Economic Uncertainty: The company acknowledges risks and uncertainties that could impact future results, including economic conditions that may affect consumer spending on chiropractic care.
Operational Transition Risks: The transition to a pure-play franchisor model involves realigning corporate costs and operations, which may present challenges in maintaining profitability and operational efficiency during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
System-wide sales guidance for 2026: Expected to range from $519 million to $552 million.
Comp sales guidance for 2026: Expected to be in the range of negative 3% to positive 3%.
Consolidated adjusted EBITDA guidance for 2026: Expected to range from $12.5 million to $13.5 million.
Clinic count projection for 2026: Net clinic count at the end of 2026 is expected to be lower than at the end of 2025 due to closures and reshaping of the portfolio.
Long-term clinic potential: Belief in potential for more than 1,800 clinics in the U.S. alone over time.
Refranchising completion timeline: Expected to complete refranchising efforts and become a pure-play franchisor by mid-2026.
Revenue target as a pure-play franchisor: Approximately 11% of system-wide sales, compared to 10.3% in 2025.
Run-rate financials post-refranchising: Gross margin expected to be 83%-85%, G&A expense 40%-42% of revenues, CapEx approximately 3% of revenues, free cash flow conversion 60%-70%, adjusted EBITDA margin 19%-21%, and net income margin 13%-15%.
Future growth scenarios: 5% revenue growth would result in adjusted EBITDA margin of 20%-22% and net income margin of 14%-16%. 10% revenue growth would result in adjusted EBITDA margin of 22%-24% and net income margin of 16%-18%.
Capital allocation priorities: Focus on growth initiatives, share repurchases, and repurchase of RD territories.
Phase 2 of transformation journey (Joint 3.0): To begin in 2027, focusing on growth through new channels, B2B, underpenetrated U.S. markets, and international expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: In the fourth quarter, the company repurchased 1.1 million shares for a total consideration of $9 million, averaging $8.45 per share. For the full year 2025, the company repurchased 1.3 million shares for a total consideration of $11.3 million, averaging $8.73 per share. At the end of 2025, $5.7 million remained on the share repurchase plan authorized in November 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you share the attrition and new patient add metrics sequentially and year-over-year?
A:The company does not provide specific metrics but focuses on active member growth, which includes drawing in new patients, converting them to a plan, and retaining them. New patient flow has been the weakest area, but early signs from new marketing efforts are positive. Conversion and attrition numbers were slightly better than last year.
Q:How are you evolving marketing initiatives for 2026?
A:The company is shifting investment from local to national to amplify brand awareness and activation, addressing AI-driven search behavior changes, focusing on in-clinic training for lead conversion, and introducing flexible plans like Align 1 and Align 2 to address attrition.
Q:How did the 3-tiered pricing pilot go, and how will it evolve?
A:The $2 increase showed minimal impact, while the $5 and $10 increases showed more benefit, with the $10 increase being the most promising. The company is testing in new markets and being cautious about rolling it out further, considering the economic impact on their target demographic.
Q:How did the comp progress throughout the quarter, and what has been seen quarter-to-date?
A:Comps were down the most in November and improved in December, partly due to timing changes in year-end promotions. Quarter-to-date trends are similar to Q4, with some early signs of improvement in leads and new patients.
Q:What is the relative performance of the remaining clinics compared to those in the Southeast that were sold?
A:The California clinics are better performers than the clinics in the Southeast.
Q:What leading indicators give confidence that comps will improve in 2026, and when can an inflection point be expected?
A:The company is encouraged by early signs from marketing initiatives and easier comps in the second half of the year. They expect the second half to show significant improvement.
Q:What are the positive early signs being observed, and was the comp decline due to higher attrition or fewer new customers?
A:Positive signs include improved SEO effectiveness, increased website activity, and a steady improvement in new patient leads. The comp decline was primarily due to fewer new customers, though conversion and attrition are also being addressed.
Q:Does the new AI SEO marketing investment significantly increase costs?
A:The investment is incremental but offset by shifting local marketing dollars to national campaigns. Overall, net marketing spend has not increased.
Q:What are the capital allocation priorities, and what growth initiatives are being considered?
A:Priorities include investing in growth initiatives like technology improvements (e.g., martech stack and user interface for wellness coordinators) and RD territory buybacks. Investments are targeted at 3% of revenues with a 25% IRR.
Q:What is the status of RD territory buybacks?
A:Active negotiations are ongoing, with some territories close to being finalized.
Q:Does the EBITDA margin target include additional marketing investments?
A:The 19%-21% EBITDA margin target includes marketing expenses funded by franchisees shifting local dollars to national campaigns.
Q:Review of Unclear Management Responses
A:Management avoided providing specific attrition and new patient add metrics, citing a focus on active member growth instead. They also did not include pricing increases in their guidance due to ongoing tests and uncertainty about results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO Bowman
SEO
Slide progress
asset purchase
buyer
buying group
capital allocation
cash flow
clinic count
consideration share
count clinic
count end
effort clinic
flow conversion
generation
improvement
income margin
intent sale
investment share
law
margin income
marketing investment
microsites
mid
mobility
model play
page
pain
purchase agreement
rate financials
return
sale Slide
sale corporate
sale system
share consideration
share repurchase
traffic
transformation journey
JYNT Transcript
The Joint Corp. (JYNT) Q1 2026 Earnings Call Transcript
Positive5-11
Despite the absence of operational and strategic updates, the financial performance shows a positive trend with revenue, net income, EBITDA, and operating margin all improving year-over-year. The company's ability to increase cash flow from operations further supports a positive outlook. The lack of concerning responses in the Q&A suggests no immediate risks were highlighted, which maintains the positive sentiment.
The Joint Corp. (JYNT) Q4 2025 Earnings Call Transcript
Unknown3-12
Despite positive full-year financial performance and optimistic marketing initiatives, the decline in comp sales and lack of specific metrics on attrition and new patient adds raise concerns. The cautious approach to pricing increases and the shift from local to national marketing may not yield immediate results. The Q&A revealed some positive signs, but uncertainties remain. Overall, the market may react neutrally over the next two weeks.
The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
The Joint Corp. (JYNT) Q2 2025 Earnings Call Transcript
Positive8-9
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
JYNT Slides
The Joint Q1 2026 slides: refranchising drives profitability surge2026-05-07
Joint Corp Q4 2025 slides: EBITDA rises 8% amid transformation push2026-03-12
The Joint Corp Q2 2025 slides: Refranchising accelerates as EBITDA jumps 52%2025-08-07
The Joint Corp Q1 2025 slides: Revenue grows 7% as franchise model expands2025-05-08
JYNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
